Hot Features
Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
PAVmed Inc is a medical device company engaged in advancing a pipeline of medical technologies from concept to commercialization using a business model focused on capital and time efficiency. Its product includes EsoCheck; CarpX; EsoGuard; PortIO; DisappEAR and others. PAVmed Inc is a medical device company engaged in advancing a pipeline of medical technologies from concept to commercialization using a business model focused on capital and time efficiency. Its product includes EsoCheck; CarpX; EsoGuard; PortIO; DisappEAR and others.
Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume PR Newswire NEW YORK, Jan. 13, 2025 Quarterly test volume of over 4,000 tests represented sequential increase of 45 percent NEW...
Lucid Diagnostics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule PR Newswire NEW YORK, Dec. 23, 2024 NEW YORK, Dec. 23, 2024 /PRNewswire/ -- Lucid...
Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters PR Newswire NEW YORK, Dec. 19, 2024 Partnership launched with fully-contracted...
Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication PR Newswire NEW YORK, Dec. 11, 2024 Study demonstrates outstanding...
Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones PR Newswire NEW YORK, Dec. 3, 2024 New convertible debt...
Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test PR Newswire NEW YORK, Nov. 20, 2024 NEW YORK, Nov. 20, 2024 /PRNewswire/...
Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum PR Newswire NEW YORK, Nov. 18, 2024 NEW YORK, Nov. 18, 2024 /PRNewswire/...
PAVmed Provides Business Update and Third Quarter 2024 Financial Results PR Newswire NEW YORK, Nov. 14, 2024 Lucid reports record quarterly EsoGuard® revenue and completes clinical evidence...
Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication PR Newswire NEW YORK, Nov. 7...
Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue Drivers PR Newswire NEW YORK, Nov. 5, 2024 Industry veterans from leading cancer...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.015051 | -2.3333038783 | 0.645051 | 0.68 | 0.5719 | 244044 | 0.63638152 | CS |
| 4 | -0.0152 | -2.35585864848 | 0.6452 | 0.76 | 0.5719 | 239379 | 0.64699398 | CS |
| 12 | -0.4 | -38.8349514563 | 1.03 | 1.25 | 0.5719 | 174097 | 0.7398391 | CS |
| 26 | -0.37 | -37 | 1 | 1.89 | 0.5719 | 110479 | 0.87139072 | CS |
| 52 | -1.7 | -72.9613733906 | 2.33 | 3.5 | 0.5719 | 87447 | 1.21332656 | CS |
| 156 | -22.77 | -97.3076923077 | 23.4 | 35.1 | 0.5719 | 582385 | 14.07526699 | CS |
| 260 | -21.57 | -97.1621621622 | 22.2 | 145.5 | 0.5719 | 1136076 | 47.53890589 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
